Verenium
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$90.0m | Late VC | ||
N/A | $7.3m | Series A | |
$62.0m Valuation: $62.0m | Acquisition | ||
Total Funding | €88.5m |
Recent News about Verenium
EditVerenium specializes in providing innovative solutions for the pharmaceutical industry, focusing on enhancing drug manufacturing processes to be more efficient, robust, and cost-effective. The company serves pharmaceutical manufacturers by offering a wide range of chemical raw materials, including APIs (Active Pharmaceutical Ingredients) like ibuprofen and omega-3. Operating in the global pharmaceuticals market, Verenium leverages its deep understanding of various industries, technologies, and applications to meet the specific needs of its clients. The business model revolves around supplying high-quality raw materials and excipients essential for drug formulation, ensuring that pharmaceutical companies can produce effective and safe medications. Verenium generates revenue through the sale of these specialized raw materials and by providing tailored solutions that address the unique challenges faced by its clients in drug production. The company is committed to sustainability and responsible care, adapting to the evolving landscape of the pharmaceutical industry, especially in light of the COVID-19 pandemic.
Keywords: pharmaceutical manufacturing, APIs, ibuprofen, omega-3, drug formulation, efficiency, robustness, cost-effectiveness, sustainability, responsible care.